Linto Thomas1, Jianxiang Xue1, Sathish Kumar Murali2, Robert A Fenton2, Jessica A Dominguez Rieg1, Timo Rieg3. 1. Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida; and. 2. Department of Biomedicine, Aarhus University, Aarhus, Denmark. 3. Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida; and trieg@health.usf.edu.
Abstract
BACKGROUND: The kidneys play an important role in phosphate homeostasis. Patients with CKD develop hyperphosphatemia in the later stages of the disease. Currently, treatment options are limited to dietary phosphate restriction and oral phosphate binders. The sodium-phosphate cotransporter Npt2a, which mediates a large proportion of phosphate reabsorption in the kidney, might be a good therapeutic target for new medications for hyperphosphatemia. METHODS: The authors assessed the effects of the first orally bioavailable Npt2a inhibitor (Npt2a-I) PF-06869206 in normal mice and mice that had undergone subtotal nephrectomy (5/6 Nx), a mouse model of CKD. Dose-response relationships of sodium, chloride, potassium, phosphate, and calcium excretion were assessed in response to the Npt2a inhibitor in both groups of mice. Expression and localization of Npt2a/c and levels of plasma phosphate, calcium, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23) were studied up to 24-hours after Npt2a-I treatment. RESULTS: In normal mice, Npt2a inhibition caused a dose-dependent increase in urinary phosphate (ED50 approximately 21 mg/kg), calcium, sodium and chloride excretion. In contrast, urinary potassium excretion, flow rate and urinary pH were not affected dose dependently. Plasma phosphate and PTH significantly decreased after 3 hours, with both returning to near baseline levels after 24 hours. Similar effects were observed in the mouse model of CKD but were reduced in magnitude. CONCLUSIONS: Npt2a inhibition causes a dose-dependent increase in phosphate, sodium and chloride excretion associated with reductions in plasma phosphate and PTH levels in normal mice and in a CKD mouse model.
BACKGROUND: The kidneys play an important role in phosphate homeostasis. Patients with CKD develop hyperphosphatemia in the later stages of the disease. Currently, treatment options are limited to dietary phosphate restriction and oral phosphate binders. The sodium-phosphate cotransporter Npt2a, which mediates a large proportion of phosphate reabsorption in the kidney, might be a good therapeutic target for new medications for hyperphosphatemia. METHODS: The authors assessed the effects of the first orally bioavailable Npt2a inhibitor (Npt2a-I) PF-06869206 in normal mice and mice that had undergone subtotal nephrectomy (5/6 Nx), a mouse model of CKD. Dose-response relationships of sodium, chloride, potassium, phosphate, and calcium excretion were assessed in response to the Npt2a inhibitor in both groups of mice. Expression and localization of Npt2a/c and levels of plasma phosphate, calcium, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23) were studied up to 24-hours after Npt2a-I treatment. RESULTS: In normal mice, Npt2a inhibition caused a dose-dependent increase in urinary phosphate (ED50 approximately 21 mg/kg), calcium, sodium and chloride excretion. In contrast, urinary potassium excretion, flow rate and urinary pH were not affected dose dependently. Plasma phosphate and PTH significantly decreased after 3 hours, with both returning to near baseline levels after 24 hours. Similar effects were observed in the mouse model of CKD but were reduced in magnitude. CONCLUSIONS:Npt2a inhibition causes a dose-dependent increase in phosphate, sodium and chloride excretion associated with reductions in plasma phosphate and PTH levels in normal mice and in a CKD mouse model.
Authors: Søren Brandt Poulsen; Tina Bøgelund Kristensen; Heddwen L Brooks; Donald E Kohan; Timo Rieg; Robert A Fenton Journal: JCI Insight Date: 2017-04-06
Authors: So Nagai; Makoto Okazaki; Hiroko Segawa; Clemens Bergwitz; Thomas Dean; John T Potts; Matthew J Mahon; Thomas J Gardella; Harald Jüppner Journal: J Biol Chem Date: 2010-11-03 Impact factor: 5.157
Authors: Robert A Fenton; Søren B Poulsen; Samantha de la Mora Chavez; Manoocher Soleimani; Meinrad Busslinger; Jessica A Dominguez Rieg; Timo Rieg Journal: Am J Physiol Renal Physiol Date: 2015-04-29
Authors: Joost G J Hoenderop; Johannes P T M van Leeuwen; Bram C J van der Eerden; Ferry F J Kersten; Annemiete W C M van der Kemp; Anne-Marie Mérillat; Jan H Waarsing; Bernard C Rossier; Volker Vallon; Edith Hummler; René J M Bindels Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Pablo Florenzano; Macarena Jimenez; Carlos R Ferreira; Galina Nesterova; Mary Scott Roberts; Sri Harsha Tella; Luis Fernandez de Castro; Rachel I Gafni; Myles Wolf; Harald Jüppner; Barbara Gales; Katherine Wesseling-Perry; Daniela Markovich; William A Gahl; Isidro B Salusky; Michael T Collins Journal: J Am Soc Nephrol Date: 2020-07-06 Impact factor: 10.121
Authors: Hannah M Costello; Jermaine G Johnston; Alexandria Juffre; G Ryan Crislip; Michelle L Gumz Journal: Physiol Rev Date: 2022-05-16 Impact factor: 46.500
Authors: Linto Thomas; Jianxiang Xue; Viktor N Tomilin; Oleh M Pochynyuk; Jessica A Dominguez Rieg; Timo Rieg Journal: Am J Physiol Renal Physiol Date: 2020-08-03
Authors: Andrew Arnold; Elaine Dennison; Christopher S Kovacs; Michael Mannstadt; René Rizzoli; Maria Luisa Brandi; Bart Clarke; Rajesh V Thakker Journal: Nat Rev Endocrinol Date: 2021-03-16 Impact factor: 43.330
Authors: Kyoungrae Kim; Erik M Anderson; Trace Thome; Guanyi Lu; Zachary R Salyers; Tomas A Cort; Kerri A O'Malley; Salvatore T Scali; Terence E Ryan Journal: Am J Physiol Renal Physiol Date: 2021-06-14